News from d-pharm ltd A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 14, 2014, 16:05 ET

Yew Bio-Pharm Group Reports 2014 Second Quarter Financial Results

Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the...

Jul 15, 2014, 08:00 ET

Yew Bio-Pharm Welcomes Two New Board Members

Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the...

Jun 12, 2014, 08:00 ET

D-Pharm's DP-b99 Prevents Abnormal Neuronal Plasticity and Pathological Brain Reorganization

D-Pharm Ltd. (TASE: DPRM) announced today, publication in PLOS ONE, of promising results from a study of its drug candidate DP-b99. The findings...

Jun 02, 2014, 08:00 ET

D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA

D-Pharm Ltd. (TASE: DPRM), Rehovot, Israel, reports today, June 2nd, 2014, the interim results for the second dose tier of stroke patients that...

May 21, 2014, 08:00 ET

Yew Bio-Pharm Group Reports 2014 First Quarter Financial Results

HARBIN, China, May 21, 2014 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: YEWB), a major grower and seller of...

Mar 31, 2014, 16:05 ET

Yew Bio-Pharm Group Reports 2013 Fourth Quarter And Full Year Financial Results

Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the...

Mar 04, 2014, 08:00 ET

D-Pharm Reports the Successful Interim Analysis of its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With the Thrombolytic Drug tPA

D-Pharm Ltd (TASE: DPRM) announced today, March 4th, 2014, the successful interim analysis of the first group of stroke patients that completed...

Jan 23, 2014, 18:43 ET

Yew Bio-Pharm Chairman & CEO Issues Letter to Shareholders

Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCQB: YEWB), a major grower and seller of yew trees, yew raw materials used in the...

Jan 21, 2014, 08:00 ET

D-Pharm Completes Recruitment of Patients into the first Dosage Tier of its Phase 2 Study with THR-18 in Acute Stroke Patients Treated with tPA

D-Pharm Ltd (TASE: DPRM) announced today, January 21st, 2014, that enrolment of patients into the first tier of its Phase 2 clinical trial with...

Jan 14, 2014, 08:00 ET

D-Pharm Announces Recruitment of the First Patient Into Its Phase 2 Clinical Trial With DP-b99 in Acute High-Risk Pancreatitis

D-Pharm Ltd (TASE: DPRM) announced today January 14th 2014, that the first patient has been recruited into its Phase 2 clinical trial of DP-b99 in...

Nov 21, 2013, 08:00 ET

D-Pharm starts Phase 2 Clinical Study with DP-b99 in Acute High-Risk Pancreatitis Patients

D-Pharm Ltd (TASE:DPRM) announced today November 21st 2013, receipt of approval from the regulatory authorities in Slovakia to commence a Phase 2...

Oct 30, 2013, 09:01 ET

D-Pharm Granted Patent in US and China for its Phase II Product THR-18

D-Pharm Ltd (TASE: DPRM) announced today, October 30 2013, that a new patent has been granted in the US and China related to composition and use...

Oct 30, 2013, 08:00 ET

D-Pharm Granted Patent in US and China for its Phase II Product THR-18

D-Pharm Ltd (TASE: DPRM) announced today, October 30 2013, that a new patent has been granted in the US and China related to composition and use...

Oct 16, 2013, 08:00 ET

D-Pharm Commences Phase 2 Study with THR-18 In Stroke Patients Treated with Tissue Plasminogen Activator (tPA)

D-Pharm Ltd (TASE: DPRM) announced today, October 16th 2013, receipt of approval from the regulatory authorities in the Ukraine to commence a...

Oct 14, 2013, 09:00 ET

D-Pharm Schedules Investigators Meeting to Discuss Protocol of Phase 2 Clinical Study of DP-b99 for Acute High-Risk Pancreatitis

D-Pharm Ltd (TASE: DPRM) announced today October 14th 2013, that an Investigators Meeting has been scheduled later this month, in Prague, to...

Sep 04, 2013, 07:18 ET

Herb Pharm Announces Collaboration With Holistic Nursing Specialist Dr. Martha Libster

 Herb Pharm, a leading grower of organic medicinal herbs and manufacturer of herbal healthcare products, announced today that it has entered...

Aug 27, 2013, 10:14 ET
Aviva Romm, MD.  (PRNewsFoto/Herb Pharm)

Herb Pharm & Aviva Romm, MD, Join Forces To Advance The Awareness & The Effective Use Of Medicinal Herbs

 Herb Pharm, a leading grower of organic medicinal herbs and manufacturer of herbal healthcare products, announced today that it has entered a...

Aug 23, 2013, 08:00 ET

Yew Bio-Pharm Group Announces Coverage by S&P Capital IQ

HARBIN, China, Aug. 23, 2013 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: YEWB), a major grower and seller...

Aug 19, 2013, 09:00 ET

Positive Results for D-Pharm's Investigational Drugs in Models of Human African Trypanosomiasis and Malaria

D-Pharm Ltd., (TASE: DPRM) announced today on-line publication of promising results with its drug candidates, DP-460 and DP-b99, in models of...

Jul 22, 2013, 08:00 ET

Yew Bio-Pharm Group Announces DTC Eligibility of Its Stock

Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the...